Colin G. Edwards

Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

Guido Marcucci, Krzysztof Mrózek, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2005 · 384 citations

Life Sciences, Genetics, Oncology +16

Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered

John C. Byrd, Richard K. Dodge, Andrew J. Carroll et al. · Journal of Clinical Oncology · 1999 · 312 citations

Medicine, Oncology, Pharmacology +16

Overexpression of the ETS-Related Gene, <i>ERG</i>, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study

Guido Marcucci, Claudia D. Baldus, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2005 · 233 citations

Life Sciences, Hematology, Oncology +17

Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461

John C. Byrd, Amy S. Ruppert, Krzysztof Mrózek et al. · Journal of Clinical Oncology · 2004 · 219 citations

Medicine, Oncology, Pharmacotherapy +14

Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461

Guido Marcucci, Krzysztof Mrózek, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2004 · 106 citations · Full text

Medicine, Hematology, Oncology +17